Introduction: Skeletal muscle depletion, referred to as sarcopenia, has recently been identified as a risk factor for poor outcomes in various malignancies. However, the prognostic significance of sarcopenia in patients with NSCLC after surgery has not been adequately determined. This study investigated the impact of sarcopenia in patients undergoing pulmonary resection for lung cancer.
Introduction
Lung cancer is the leading cause of cancer death in many countries, and NSCLC accounts for approximately 75% to 80% of primary lung cancer.
1,2 Surgical resection is a potentially curative treatment for NSCLC, but recurrence develop in 27% to 38% of patients after surgical resection of stage I NSCLC. 3 The postoperative prognosis for NSCLC patients can be determined by the TNM staging system. 4 However, tumor-specific factors are not the only determinants of postoperative prognosis: physical factors, such as body mass index and performance status, are also influential. loss of skeletal muscle mass and function, with a risk of adverse outcomes such as physical disability, poor quality of life, and death, has been identified as a prognostic factor for various cancers. [8] [9] [10] [11] Determination of sarcopenia in patients can be achieved using various imaging techniques to assess skeletal muscle mass, such as dual-energy x-ray absorptiometry, computed tomography (CT), magnetic resonance imaging (MRI), and bioimpedance analysis (BIA). 8, 12, 13 Some investigators have evaluated the depletion of muscle mass using CT image in various cancers. [9] [10] [11] Furthermore, CT has become a routine diagnostic tool for cancer and lung cancer staging with primary lesion and metastatic lesions. Sarcopenia was originally a concept determined by using the data from "healthy" subjects. A method of measuring psoas muscle mass index (PMI) at the third lumbar level on CT was proposed for assessing the skeletal muscle mass. 13 As it was a convenient and inexpensive method that could be performed in routine practice, we conducted a retrospective study using the cutoff level calculated by this method to investigate the relationship between sarcopenia and treatment outcomes of surgically resected lung cancer patients using preoperative CT for lung cancer staging.
Patients and Methods

Patients
This retrospective study was approved by the ethics committee of the Mito Medical Center Institutional Review Board. Between January 2005 and April 2017, 351 patients who underwent lung resection with curative intent at our institution were identified. All patients had CT scans before surgery for diagnosis and lung cancer staging. Among those patients, a total of 328 patient preoperative CT scans were evaluated at the third lumber vertebrae level. The histologic classification of tumor was based on WHO histologic classification of lung cancer, and the pathologic stage was determined according to the TNM criteria from the eighth edition of the Union for International Cancer Control Classification. 14, 15 All patients up to December 2016 were reclassified with the TNM eighth edition, and those after January 2017 were classified with the TNM eighth edition.
Image Analysis
All preoperative CT scans were obtained within 2 months before surgery. Muscle volume and manual tracing of the cross-sectional area of the right and left psoas muscle were determined using preoperative CT at the level of the caudal end of the third lumber vertebra (Fig. 1) . Measurements were performed in the Picture Archive and Communication System, and the total psoas area was then normalized for height. PMI was calculated as follows:
PMI ¼ cross-sectional area of the bilateral psoas muscle/height 2 (cm 2 /m 2 ) The PMI cutoff value for sarcopenia was defined as 6.36 cm 2 /m 2 for men and 3.92 cm 2 /m 2 for women, which were described by Hamaguchi et al. 13 
Postoperative Complication
We assessed the postoperative complications using the Clavien-Dindo classification system. 16 The ClavienDindo grades are as follows: grade 1 (any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic, and radiological interventions), grade 2 (requiring pharmacological treatment), grade 3 (requiring surgical, endoscopic or radiological intervention), grade 4 (lifethreatening complication requiring intensive care/ intensive care unit management), and grade 5 (patient death). We defined a major complication as a classification of grade 3 or higher.
Statistical Analysis
The Mann-Whitney U test and Fisher's exact test were used to compare groups and categorical variables. With regard to correlation, we used Spearman's rank correlation coefficient. Survival curves were constructed using the Kaplan-Meier method and overall survival (OS) rates were compared using log-rank test. Cox hazard models were used to identify prognostic factors of survival. Any factors with p < 0.10 in univariate analysis using the above tests were considered to for multivariate analysis. All analyses were performed using SPSS version 23 (IBM Corporation, Armonk, New York). A p value of <0.05 was considered statistically significant. 
Results
The clinical and pathologic characteristics of all 328 patients are shown in ) (p < 0.001) ( Fig. 2A) . The prevalence of patients with PMI below the cutoff value, that is, sarcopenia patients, was 55.8% (67.7% for men and 38.3% for women). PMI was significantly negatively correlated with age in both males (p < 0.001, r ¼ -0.038) and females (p ¼ 0.025, r ¼ -0.020) ( Fig. 2B and C) . Figure 2D shows the prevalence of patients with sarcopenia for every 5 years of age. From the age of 64 years to the age of 84 years, the prevalence of sarcopenia patients increased with age. Patients older than 85 years of age had a lower prevalence of sarcopenia than those aged 80 to 84 years. The prevalence of patients with sarcopenia by age for each gender is shown in Figure 2E and F. In male patients, the prevalence of sarcopenia in each age group accounted for more than half, and the prevalence increased with age. On the other hand, in female patients, the prevalence increased with age until 75 to 79 years old, but the prevalence of those with sarcopenia was less than half up to 70 to 74 years of age. The prevalence was similar in patients older than 75 to 79 years of age, and this decreased in patients older than 85 years of age.
Characteristics of patients with and without sarcopenia are summarized in Table 2 . There were significant differences in age, sex, and smoking history. Body mass index in the sarcopenia group was significantly lower than that in the group without sarcopenia, whereas the prevalence of patients with diabetes mellitus did not differ between the two groups. The prevalence of patients with elevated serum carcinoembryonic antigen (CEA) levels varied between the two groups. Regarding pathologic characteristics, there was a significant difference in histologic type, whereas there was no significant difference in the surgical procedure, pathologic stage, pleural invasion, lymphatic permeation, and vascular invasion. Postoperative major complications were significantly different between the two groups.
Kaplan-Meier analysis showed significantly worse OS in patients with sarcopenia (Fig. 3) . Univariate analysis of several clinical factors on survival after surgery for lung cancer is shown in Table 3 . Age older than 70 years, male sex, smoking habit, vital capacity <80%, elevation of CEA, and sarcopenia were unfavorable factors for OS. In terms of pathologic factors, nonadenocarcinoma, advanced pathologic stage, presence of visceral pleural invasion, and presence of lymphatic permeation and vascular invasion were associated with a worse outcome. Postoperative major complications were related with unfavorable outcomes. In addition, multivariate analysis showed that age older than 70 years, male sex, elevation of CEA, and advanced pathological stage were poor prognostic factors in the survival of resected lung cancer patients. In addition, sarcopenia was found to be an unfavorable factor in the multivariate analysis (Table 3) .
Discussion
Sarcopenia was initially defined as the age-related loss of skeletal muscle mass. 17 The European Working Group on Sarcopenia in Older People (EWGOP) and Asian Working Group on Sarcopenia (AWGS) recommended the necessity of measuring and evaluating both muscle mass and function to diagnose sarcopenia. Body composition can be evaluated using several modalities, such as dual-energy x-ray absorptiometry, CT, MRI, and BIA. According to EWGOP, CT and MRI were the gold standards for estimating muscle mass. On the other hand, AWGS recommended using BIA. 8, 12 As described above, the complex discussion of sarcopenia involves July 2018 Sarcopenia in Resected NSCLCmany measurement modalities, complicated forms of analysis, and proposed cutoff values. In cancer practice in Japan, CT is being performed as a routine examination, and muscle mass can be sufficiently evaluated by CT. Therefore, instead of using a new test, CT will be useful for evaluating muscle mass. With these insights, Hamaguchi et al. 13 made the following proposal. They investigated PMI at the third lumbar level based on CT, and PMI was highly correlated with skeletal muscle index measured by BIA. They concluded that the cutoff value of PMI was 6.36 cm 2 /m 2 for men and 3.92 cm 2 /m 2 for women. 13 Sarcopenia was originally a concept determined by using the data from "healthy" subjects, not the determined cutoff for each disease. Therefore, we considered that determining the cutoff value using data from healthy subjects was appropriate in this study. The method of measuring PMI at the third lumbar level on CT used in this study was a method that did not require special software for analysis. Therefore, it was a simple and inexpensive method that could be performed in routine practice. The disadvantage of this method might be potential inaccuracy because PMI is measured at a site that is artificially selected on the CT level. However, it might be useful as a method for quickly measuring skeletal muscle mass index within the limited time frames of outpatient clinical practice.
Sarcopenia characterizes cancer cachexia, a multifactorial syndrome leading to progressive functional impairment that cannot be fully reversed by conventional nutritional support. According to Fearon et al., 18 
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Sarcopenia in Resected NSCLCdiagnostic criteria for cancer cachexia must inevitably include additional information beyond merely assessing weight loss, such as the presence of skeletal muscle wasting, anorexia, and inflammation. The cachexia syndrome can develop progressively through various stages from pre-cachexia to cachexia to refractory cachexia. Severity can be classified according to degree of depletion of energy stores and body protein in combination with degree of ongoing weight loss. Cancer cachexia contributes to poor prognosis through progressive depletion of the body's energy and protein reserves. 19 One of the agreed diagnostic criteria for cancer cachexia is sarcopenia, severe skeletal muscle mass; although several proposals have been made regarding the definition and evaluation method of sarcopenia itself.
The relationship between sarcopenia and postoperative complications has been described in other malignancies in addition to lung cancer. [20] [21] [22] Sarcopenia was present in 25% to 38.9% of colorectal and pancreatic cancer and has been noted to increase the risk of postoperative infection in these patients. 10, 11, 20, 21, [20] [21] [22] Reisinger et al. 22 reported that sarcopenia in patients with surgically resected colorectal cancer was associated with an increased postoperative inflammatory response, and that this response might play a role of the high incidence of postoperative complications in patients with sarcopenia.
In various malignancies other than lung cancer, sarcopenia was an independent poor prognostic factor in multivariate analysis. 10, 11, 23, 24 However, there were few articles on sarcopenia in patients with lung cancer.
9,25-27 Prado et al. 9 identified that sarcopenic obesity was an independent predictor of survival in 2115 patients with solid tumors of the respiratory or gastrointestinal tract, although many patients were in an advanced stage of disease. There are two reports on NSCLC patients who received surgical resection. One of them was a report on 90 patients with stage I NSCLC, and another report showed a relationship between the lower pectoralis muscle area and prognosis. 26, 27 In this study, we found that the 5-year survival rate in patients with sarcopenia was significantly poorer than in those without sarcopenia. Of the prognostic factors, sarcopenia was the only preoperative factor that could be improved. Prognosis after resection of Figure 3 . The overall survival curves in patients with and without sarcopenia. lung cancer depends on several tumor-specific factors, including tumor size, lymph node metastasis, pleural invasion, and pulmonary metastasis. These tumorspecific factors were found by postoperative pathologic examination. Sarcopenia was associated with major surgical complications in our study, so we believe that the clinical management of patients with sarcopenia before surgery, such as nutrition management and rehabilitation, could improve postoperative outcomes.
There have been some reports with the impact of sarcopenia on the toxicity of chemotherapy in various malignancies. In neoadjuvant chemotherapy, adjuvant chemotherapy, and palliative chemotherapy, these researchers concluded that patients with sarcopenia had higher risk of complications associated with chemotherapy. [28] [29] [30] [31] As Jung et al. 29 reported, therefore, when conducting postoperative chemotherapy in patients with sarcopenia, surgery should be carefully performed.
Several mechanisms have been proposed to explain the association between sarcopenia and treatment. [32] [33] [34] Skeletal muscle has recently been identified as a secretory organ and it produces the growth hormone myokine, which suppresses the growth of cancer cells and is involved in the control of immune cells. 35, 36 Therefore, reduced muscle mass could lead to an impaired myokine response and an increased risk of cancer relapse.
Our present study also showed that postoperative major complications (Clavien-Dindo grade 3) were significantly associated with sarcopenia. Patients with sarcopenia may have many complications and short OS rates. Therefore, if the presence of sarcopenia is known before surgery, the necessary and appropriate postoperative management can be provided for patients with sarcopenia. Furthermore, it is supposed that they can be given the opportunity to reconsider the selection of surgical method or treatment method other than surgery. It is well-known that muscle mass can recover through nutrition management by administration of nutrients and rehabilitation before surgery. [37] [38] [39] [40] Interestingly, a previous study by Yamada et al. 41 on community-dwelling older adults showed that the prevalence of sarcopenia increased age-dependently, especially in those older than 75 years in both genders. In those younger than 75 years old, the prevalence of sarcopenia was higher in women than in men; however, in those older than 85 years, the prevalence of sarcopenia was lower in women than in men. In addition, fall incidents and fear of falling were more prevalent in sarcopenic older adults than in nonsarcopenic older adults. 41 Some results in this study were contradicted by our findings. The reason for the disparity may depend on the subjects studied, community-dwelling older adults in the study by Yamada et al., 41 and resectable NSCLC patients in our study. In the present study, the prevalence of patients with sarcopenia increased with age in men, whereas the prevalence did not increase in females older than 70 years.
There are several shortcomings associated with the retrospective design of this study. The data were obtained from a review of hospital records of NSCLC patients over a long-term period in a single institute and the sample size was limited. There is also a possibility that the PMI evaluation method could be improved. In addition, there were many factors related to long-term survival of NSCLC postoperatively, including TNM staging, histologic classification, age, gender, et cetera. Although we evaluated these factors by uni-and multivariate analyses, we could not exclude the possibility that these factors were statistically confounded. We are planning a multi-institutional prospective clinical trial in these patients to confirm the results of this study.
In summary, our study shows the clinical value of determining sarcopenia using PMI on CT for patients with NSCLC. By having information about sarcopenia before surgery, clinicians could take preventive measures against potential complications. The importance of preoperative nutritional management and rehabilitation will be clarified. This study also provides important information for concrete program planning for preoperative management.
